Dr Yangzhou Wang, chief operations officer of Crown Bioscience (CrownBio), shares the new era of development for the company following its acquisition by a Japanese industrial conglomerate in December 2017; CrownBio’s biology-driven deep expertise in oncology drug discovery and development and how it will continue to drive the company’s growth; and his conviction that China will be the next frontier of biopharma innovation in addition to the US.
If you compare pharma industry development to a series of gold rushes, the pharma companies are the ones panning for the gold and we are the people by the side selling them the shovels
